Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jean Wallner

Physician Assistant Tampa, FL Physician Assistant

NPI 1639220973 CMS profile 11156555

7001 N Dale Mabry Hwy Ste 10, Tampa, FL 33614

Open in the dashboard

General payments

$12,129

338 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jean Wallner of Tampa, FL is reported in the CMS Open Payments database as having received $12,129 across 338 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,581 40
2024 General $1,711 48
2023 General $1,394 56
2022 General $1,876 87
2021 General $2,567 107

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jean Wallner
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jean Wallner were reported at $4,581. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jean Wallner Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,567 $132 $37–$438 $132
2022 $1,876 $155 $48–$522 $149
2023 $1,394 $167 $52–$557 $160
2024 $1,711 $178 $55–$600 $164
2025 $4,581 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $4,306 24 payments
  2. Amgen Inc. $2,472 78 payments
  3. Novartis Pharmaceuticals Corporation $876 51 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $620 25 payments
  5. Esperion Therapeutics, Inc. $545 17 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $516 27 payments
  7. AstraZeneca Pharmaceuticals LP $491 17 payments
  8. Pfizer Inc. $342 17 payments
  9. Novo Nordisk Inc $276 8 payments
  10. Boston Scientific Corporation $270 10 payments
  11. Other $1,415 64 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,802 329 payments
  2. Consulting Fee $2,423 4 payments
  3. Travel and Lodging $854 2 payments
  4. Education $50 3 payments
Products named General payments · program years 2021–2025
  1. EVKEEZA Cardiovascular And Metabolic $3,717 12 payments
  2. Repatha Cardiology $1,603 59 payments
  3. EVKEEZA Cardiovascular And Metabolism $707 14 payments
  4. ENTRESTO $582 33 payments
  5. NEXLETOL $545 17 payments
  6. LifeVest $516 27 payments
  7. JARDIANCE $483 20 payments
  8. NEXLIZET $319 4 payments
  9. FARXIGA $309 6 payments
  10. REPATHA Cardiovascular $287 11 payments
  11. Other $3,425 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,071

Median for Physician Assistant: 241

Drug cost

$228,156

Median for Physician Assistant: $4,110

Branded share of claims

26.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Repatha Sureclick Evolocumab Brand 85 $90,409
Eliquis Apixaban Brand 59 $59,625
Entresto Sacubitril/Valsartan Brand 24 $32,861
Praluent Pen Alirocumab Brand 33 $24,664
Ozempic Semaglutide Brand 11 $10,271
Rosuvastatin Calcium Generic 113 $1,627
Ezetimibe Generic 123 $1,524
Atorvastatin Calcium Generic 130 $1,325
Metoprolol Succinate Generic 119 $1,192
Valsartan Generic 28 $836

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$16,803

Medicare's payments for the services billed

Medicare patients

114

Average age 76

Services billed

229

69 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Arthritis 59%
Diabetes 53%
Chronic kidney disease 48%
Heart failure 38%
Depression 37%
Atrial fibrillation 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVKEEZA
  • Regeneron Healthcare Solutions, Inc. $266
  • Regeneron Pharmaceuticals, Inc. $17
$283 — —
Repatha
  • Amgen Inc. $228
$228 85 —
Wegovy
  • Novo Nordisk Inc $146
$146 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $120
$120 — —
Ozempic
  • Novo Nordisk Inc $57
$57 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

338 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record